Skip to main content
. 2022 Oct 31;12:1037523. doi: 10.3389/fonc.2022.1037523

Figure 6.

Figure 6

Relationship between plasma exosomal tRF-Ala-AGC-036 and tumor stage. (A) (B) Expression levels of exosomal tRF-Ala-AGC-036 in T and N stages NSCLC patients. (C) The expression level of exosomal tRF-Ala-AGC-036 of NSCLC patients with advanced stage (III-IV) was lower than that of NSCLC patients with early-stage (0- II). (D) Exosomal tRF-Ala-AGC-036 was downregulated in M1 stage NSCLC patients compared with M0 stage NSCLC patients. (E) ROC curve analysis of exosomal tRF-Ala-AGC-036 for M1 stage NSCLC patients relative to M0 stage NSCLC patients (*p < 0.05, **p < 0.01, ***p < 0.001).